REWRITING THE RULES OF DRUG CREATION
Live / Applied — Third extension granted (statement of use) (as of 18 Nov 2025)
What this means for you
Not registered yet, but its 07 Oct 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97623507
- Mark type
- Stylized text
- Filed
- 07 Oct 2022
- Published for opposition
- 26 Mar 2024
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders
- Class 042 — Scientific and technological services: Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; drug development and discovery; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable computer software involving the use of artificial intelligence technology for molecular design; scientific diagnostic and screening services, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks
- Class 044 — Medical, beauty and agricultural services: Medical diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases
Owner
- Cellarity, Inc., Somerville, MA, US
- Cellarity, Inc., Somerville, MA, US
Prosecution history
- 19 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Nov 2025 — SOU EXTENSION 3 GRANTED
- 18 Nov 2025 — SOU EXTENSION 3 FILED
- 18 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 17 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 May 2025 — SOU EXTENSION 2 GRANTED
- 16 May 2025 — SOU EXTENSION 2 FILED
- 16 May 2025 — SOU TEAS EXTENSION RECEIVED
- 30 Jan 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Jan 2025 — SOU EXTENSION 1 GRANTED
- 14 Nov 2024 — SOU EXTENSION 1 FILED
- 30 Dec 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 14 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 21 May 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Mar 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED